Search

Sustainability

Actions we're taking to reduce the environmental impact of our flagship event: the EHA Congress.

Read more

EHA-AAH Balkan Hematology Tutorial 2022

EHA is joined forces with the Albanian Association of Hematology (AAH) to organize the EHA-AAH Balkan Hematology Tutorial.

Read more

EHA-Balkan Hematology Day 2024

EHA is joining forces with the national societies from the Balkan countries and co-organizing with them the 5th edition of the EHA-Balkan Hematology Day.

Read more

EHA undersigns Manifesto on Treatment Optimization

EHA has given its formal endorsement to the “Manifesto for a new approach for better medicine in Europe: Establishing Treatment Optimization as part of personalized medicine development”.

Read more

Myeloproliferative Neoplasms (MPN)

The aims of the SWG are furthering collaboration and sharing knowledge between centers involved in the management of MPN, a focus to develop centers and clinicians who would be willing to host visiting staff for sabbaticals or learning experiences was…

Read more

First CMML guidelines produced by EHA, now available

Chronic myelomonocytic leukemia (CMML) is a rare disease with overlapping features of two categories of bone marrow and blood cell disorders that poses challenges in clinical management.

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more